

Dengfu Yao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4046930/publications.pdf>

Version: 2024-02-01

33
papers

659
citations

623734

14
h-index

677142

22
g-index

36
all docs

36
docs citations

36
times ranked

849
citing authors

#	ARTICLE	IF	CITATIONS
1	Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3 β / β -catenin axis. <i>Journal of Translational Medicine</i> , 2020, 18, 81.	4.4	33
2	Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. <i>Current Medicinal Chemistry</i> , 2020, 27, 3290-3301.	2.4	5
3	Oncogenic Wnt3a: A Candidate Specific Marker and Novel Molecular Target for Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 5862-5873.	2.5	20
4	The application of bio-nanotechnology in tumor diagnosis and treatment: a view. <i>Nanotechnology Reviews</i> , 2018, 7, 257-266.	5.8	22
5	Role of secretory clusterin in hepatocarcinogenesis. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 48-48.	3.0	14
6	High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 5979-5989.	1.9	13
7	Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. <i>Oncotarget</i> , 2017, 8, 52321-52332.	1.8	16
8	Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. <i>BioScience Trends</i> , 2016, 10, 337-343.	3.4	14
9	IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo. <i>Tumor Biology</i> , 2016, 37, 14677-14686.	1.8	7
10	Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 5561-5568.	1.8	13
11	Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 999-1008.	1.8	17
12	Clinic expert information extraction based on domain model and block importance model. <i>Computers in Biology and Medicine</i> , 2015, 66, 337-342.	7.0	1
13	Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells. <i>Tumor Biology</i> , 2015, 36, 3995-4003.	1.8	16
14	Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma. <i>Tumor Biology</i> , 2015, 36, 9373-9383.	1.8	32
15	Down-regulating Glypican-3 Expression: Molecular-targeted Therapy for Hepatocellular Carcinoma. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 14, 1183-1193.	2.4	8
16	Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 15, 453-460.	1.7	10
17	Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis. <i>Hepatitis Monthly</i> , 2015, 15, e32918.	0.2	17
18	Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. <i>Tumor Biology</i> , 2014, 35, 9-20.	1.8	61

#	ARTICLE	IF	CITATIONS
19	Expression of Src Suppressed C Kinase Substrate in Rat Neural Tissues During Inflammation. <i>Neurochemical Research</i> , 2014, 39, 748-757.	3.3	2
20	Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy. <i>Tumor Biology</i> , 2014, 35, 5857-5868.	1.8	21
21	Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells. <i>Tumor Biology</i> , 2013, 34, 3397-3405.	1.8	8
22	Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA. <i>Tumor Biology</i> , 2013, 34, 661-668.	1.8	12
23	Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression. <i>Tumor Biology</i> , 2012, 33, 1767-1776.	1.8	24
24	Abnormal expression of hypoxia inducible factor-1 α and clinical values of molecular-targeted interference in hepatocellular carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 125-129.	0.1	3
25	Expression characteristics of HIF-1 α and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. <i>Hepatitis Monthly</i> , 2011, 11, 821-828.	0.2	39
26	Expression Characteristics of Hypoxia-Inducible Factor-1 α and Its Clinical Values in Diagnosis and Prognosis of Hepatocellular Carcinoma. <i>Hepatitis Monthly</i> , 2011, 11, 821-828.	0.2	27
27	Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. <i>Tumor Biology</i> , 2010, 31, 605-611.	1.8	11
28	Characteristics of Hepatic IGF-II Expression and Monitored Levels of Circulating IGF-II mRNA in Metastasis of Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2010, 134, 799-806.	0.7	43
29	Quantitative analysis of hepatoma-specific α -fetoprotein (HS-AFP) by a new mini-column affinity chromatography and its clinical value in diagnosis of hepatocellular carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 131-134.	0.1	1
30	Abnormal expression of hepatoma specific α -glutamyl transferase and alteration of α -glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. , 2000, 88, 761-769.		120
31	Abnormal expression of hepatoma specific α -glutamyl transferase and alteration of α -glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. <i>Cancer</i> , 2000, 88, 761-769.	4.1	5
32	Oncogenic Secretory Clusterin: A Promising Therapeutic Target for Hepatocellular Carcinoma. , 0, , .		0
33	Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma. <i>Oncotarget</i> , 0, 7, 42150-42158.	1.8	21